Gastrointestinal Transit in PBPK

1. What Is Gastrointestinal Transit?

Gastrointestinal (GI) transit describes the movement of swallowed material through the gastrointestinal tract. For an orally administered drug, transit determines how long the drug remains in the stomach and different intestinal regions before reaching downstream compartments.

In PBPK modeling, this movement matters because a drug can only dissolve, permeate, undergo intestinal metabolism, or interact with local physiological conditions while it is present in the relevant region. Transit therefore connects gastrointestinal physiology to the time available for drug absorption.

2. Why Does Transit Matter in PBPK?

A mechanistic oral absorption model needs to represent both the properties of the drug and the physiological environment through which the drug travels. Transit is one of the links between those two components.

For example, a drug may have limited aqueous solubility but adequate permeability. If it moves rapidly through a region in which dissolution is occurring, less dissolved drug may become available for absorption before the drug progresses downstream.

Conversely, a drug with rapid dissolution and high permeability may be relatively insensitive to moderate changes in transit, provided that absorption is not otherwise limited.

3. The Gastrointestinal Tract as a PBPK System

The GI tract is heterogeneous. The stomach and different intestinal regions differ in volume, pH, fluid composition, surface area, transit behavior, enzyme and transporter expression, and other physiological characteristics.

For this reason, a mechanistic absorption model generally does not treat the entire GI tract as one homogeneous compartment. Instead, it may represent several sequential regions through which the drug moves.

The exact number and definition of compartments depend on the modeling framework. A compartment in an absorption model is a mathematical representation of a physiological region; it should not automatically be interpreted as a literal anatomical container.

4. Gastric Emptying

Gastric emptying describes the transfer of stomach contents into the small intestine. For many immediate-release oral drugs, this process is an important determinant of the timing of intestinal drug availability.

The stomach is often modeled as an input compartment. Drug enters the stomach after oral administration, and gastric contents subsequently move into the small intestine according to an assumed gastric-emptying process.

A simple first-order representation can be written as:

where \(A_G(t)\) is the amount of drug in the gastric compartment and \(k_G\) is an effective gastric-emptying rate constant.

Under this simplified assumption:

and the corresponding gastric emptying flux is:

5. Transit Through the Small Intestine

After gastric emptying, drug material enters the small intestine. The small intestine is especially important for oral absorption because it provides extensive surface area and contains the physiological machinery required for dissolution, permeation, transport, and metabolism.

A mechanistic absorption model may represent the small intestine as a series of sequential compartments:

where \(G\) represents the stomach and \(D_1,\ldots,D_n\) represent sequential intestinal regions.

A simple transit model can use a common first-order transfer rate:

where \(A_i\) is the amount in intestinal compartment \(i\) and \(k_T\) controls the rate of movement through the sequence.

This type of representation turns a continuous physical process into a series of mathematical states. The greater the number of compartments, the more closely the model can approximate distributed transit behavior, although additional complexity also introduces additional assumptions and parameters.

6. What Is Transit Time?

Transit time is the amount of time material spends moving through a particular region or through the gastrointestinal tract as a whole.

Several transit measures can be distinguished:

Observed human transit times vary considerably across studies and depend on methodology and physiological conditions. A systematic review of ingestible-capsule studies reported ranges of approximately 0.4–15.3 hours for gastric emptying, 3.3–7 hours for small-intestinal transit, 15.9–28.9 hours for colonic transit, and 23.0–37.4 hours for whole-gut transit among the studies reviewed. These should be regarded as literature ranges rather than universal constants. :contentReference[oaicite:1]{index=1}

7. Transit Is a Distribution, Not Just One Number

One of the most important concepts in mechanistic GI modeling is that transit does not necessarily occur at exactly one fixed time.

Suppose every molecule of drug left the stomach at exactly 30 minutes. A model based on that assumption would produce a sharp, deterministic transition. Real biological systems are more heterogeneous.

Different portions of the dose may leave the stomach at different times. Similarly, different particles may move through intestinal regions at different rates.

A more realistic conceptual model therefore describes a transit-time distribution.

This distinction becomes especially important when absorption is sensitive to the amount of time available in a particular region. The shape of the transit distribution can influence the predicted timing and extent of absorption.

8. Fed Versus Fasted Transit

Gastrointestinal physiology differs between fed and fasted conditions. Food can alter gastric emptying, intestinal fluid volumes, pH, bile secretion, motility, and other physiological processes relevant to oral drug absorption. :contentReference[oaicite:2]{index=2}

One of the most important consequences is that the timing of drug delivery from the stomach into the intestine can change after a meal.

A PBPK model intended to predict a food effect therefore may need to change physiological inputs between fed and fasted simulations rather than simply applying an empirical multiplier to exposure.

9. Transit and Dosage-Form Behavior

Transit becomes particularly important when the dosage form itself has time-dependent behavior.

For an immediate-release tablet, the sequence may be approximated conceptually as:

For a modified-release product, drug release may continue while the dosage form travels through multiple GI regions:

In this setting, the relationship between release time and transit time can become critical. If release occurs primarily in a region with limited absorption, a portion of the released drug may contribute less to systemic exposure than expected.

10. Transit Determines the Window for Absorption

For a drug to be absorbed from the intestine, it must first be present in an absorbable form and encounter an appropriate absorptive surface.

A simplified relationship can be written as:

Transit enters this relationship because the drug has only a finite amount of time to interact with the intestinal environment.

If \(A_i(t)\) is the amount of drug in an intestinal region and \(k_{a,i}\) is an effective absorption rate constant, a simplified absorption flux might be written as:

The total amount absorbed from the region is then related to the integral of this flux over time:

The actual mechanistic implementation may instead calculate absorption from permeability, surface area, concentration gradients, unstirred layers, transporter processes, and other physiological factors.

11. The Finite Absorption Window

Transit provides a useful way to understand why oral absorption can be viewed as occurring over a finite physiological window.

If a drug moves through an absorptive region and eventually exits that region, absorption cannot continue indefinitely from that location.

Conceptually:

This does not mean that every drug stops absorbing at one precisely defined time. Rather, the available time for absorption is constrained by movement through the GI tract.

Mechanistic studies of oral absorption have also considered finite absorption time explicitly. Comparisons of physiologically based absorption models with finite-absorption-time approaches have found estimated absorption times that fall within the general scale of small-intestinal transit for the immediate-release compounds examined. :contentReference[oaicite:3]{index=3}

12. Transit Interacts With Drug Dissolution

For many oral formulations, absorption cannot begin at the full administered dose because the drug first has to become dissolved or otherwise available for absorption.

A simplified sequence is:

Transit determines the physiological environment in which dissolution occurs. As the drug moves through the GI tract, pH, fluid volume, bile components, and other conditions can change.

This creates an important interaction:

13. Why Regional Transit Matters

Not every part of the small intestine is physiologically identical. Drug absorption may therefore depend not only on total intestinal transit time but also on where the drug spends that time.

A drug may encounter different:

• luminal pH conditions;
• fluid volumes;
• surface-area characteristics;
• transporter abundances;
• metabolic enzyme expression;
• bile concentrations; and
• local physiological environments.

This is one reason mechanistic oral absorption models divide the GI tract into sequential regions rather than treating it as one undifferentiated tube.

14. How Is GI Transit Represented Mathematically?

There are several ways to represent transit in a mechanistic model. The appropriate choice depends on the scientific question, available data, and desired level of physiological detail.

Commercial mechanistic absorption platforms use compartmental absorption and transit concepts to represent processes such as intestinal dissolution, precipitation, absorption, and intestinal metabolism. :contentReference[oaicite:4]{index=4}

15. Worked Example: A Simple Transit Model

Consider a hypothetical oral dose that enters a gastric compartment. Suppose the effective gastric-emptying half-life is 30 minutes.

Step 1: Convert half-life to a rate constant

Step 2: Calculate the fraction remaining in the stomach after 1 hour

Approximately 25% of the initial amount remains under this simple first-order assumption.

Step 3: Calculate the fraction that has emptied

Thus approximately 75% of the initial gastric amount has entered the downstream compartment after one hour in this simplified model.

Step 4: Why this matters for PBPK

The 75% figure is not itself an absorption fraction. It only describes transfer out of the stomach. The material that reaches the small intestine still has to dissolve, remain chemically stable, become available for absorption, cross the intestinal wall, and potentially undergo intestinal and hepatic first-pass processes.

16. How Changes in Transit Can Change PK

The effect of a transit change depends strongly on the properties of the drug and formulation.

Consider two hypothetical drugs:

This illustrates why changing a physiological transit parameter in isolation is not enough to understand the resulting PK effect. The result depends on the interaction among transit, dissolution, permeability, formulation behavior, and other physiological processes.

Sensitivity analysis can therefore be useful. A modeler might vary gastric-emptying or intestinal-transit parameters over a plausible range and examine changes in predicted \(C_{\max}\), \(T_{\max}\), AUC, and regional absorption.

17. Gastrointestinal Transit and Food Effects

Food effects are an important application of mechanistic GI modeling. A meal can change gastric emptying and multiple other aspects of gastrointestinal physiology, which can alter the timing and extent of drug absorption. :contentReference[oaicite:5]{index=5}

A conceptual PBPK comparison might therefore be:

The difference between these simulations can arise from several mechanisms simultaneously. For example, food may alter gastric emptying, luminal fluid conditions, bile secretion, and other physiological factors. :contentReference[oaicite:6]{index=6}

This mechanistic decomposition can be more informative than simply describing a food effect as an empirical increase or decrease in AUC.

18. Transit and Gastrointestinal Drug Interactions

GI transit can also contribute to drug-drug interactions when a concomitant drug changes gastrointestinal physiology.

Examples of mechanisms that may alter oral absorption include changes in:

• gastric emptying;
• intestinal transit;
• gastric or intestinal pH;
• luminal fluid conditions;
• bile secretion;
• intestinal transport; and
• intestinal metabolism.

PBPK models can incorporate these mechanisms so that a change in physiology propagates through dissolution and absorption rather than being represented solely as an empirical exposure adjustment. Recent reviews describe gastric emptying, GI transit, and food effects as important mechanisms in absorption-mediated drug interactions. :contentReference[oaicite:7]{index=7}

19. Interindividual Variability in GI Transit

People do not all have identical gastrointestinal physiology. Transit can vary with age, body size, food intake, disease state, medications, and other physiological factors.

This matters because a population PBPK model is not simply a single deterministic human. It can represent a distribution of physiological characteristics across a virtual population.

For a physiological parameter \(P\), a population model might conceptually represent:

where \(P_j\) is the parameter for individual \(j\), \(P_{\mathrm{typical}}\) is the typical population value, and \(\eta_j\) represents between-individual variability on a log scale.

The precise statistical implementation depends on the PBPK framework. The important point is that physiological uncertainty and variability can propagate into predicted exposure.

20. Transit in Special Populations

Changes in GI physiology can be relevant when predicting pharmacokinetics in populations that differ from the healthy adult population.

The objective is not to assume that a particular population always has a specific transit change. Rather, the PBPK model should use evidence-supported physiological assumptions appropriate to the population being simulated.

21. How Should Transit Parameters Be Evaluated?

Transit parameters are physiological inputs, but their values may be uncertain. Model development should therefore distinguish between parameters supported directly by physiological evidence and parameters that are estimated or calibrated against drug-specific data.

A useful workflow is:

1. Identify the physiological parameter. Define exactly what the transit parameter represents.
2. Review the available physiological evidence. Consider population, fed/fasted state, methodology, and study design.
3. Specify an appropriate distribution or range. Avoid treating uncertain physiological quantities as exact constants.
4. Perform sensitivity analysis. Determine whether predicted PK is materially affected by the parameter.
5. Separate physiology from drug-specific parameters. Avoid using drug PK data to compensate for an inappropriate physiological assumption without recognizing what is being calibrated.
6. Evaluate predictions against independent observations. Model performance should be assessed using relevant observed data whenever possible.

22. What GI Transit Models Do Not Automatically Tell Us

A mechanistic representation of GI transit can be extremely useful, but it remains a model of a complex biological system.

• One transit time is not universal. Transit varies among individuals and conditions.
• Transit does not equal absorption. Movement through the GI tract is only one component of oral bioavailability.
• Transit does not determine exposure by itself. Drug properties, formulation, dissolution, permeability, metabolism, and elimination also matter.
• Parameter identifiability can be limited. Several physiological mechanisms may produce similar plasma concentration-time profiles.
• Fed and fasted states are not defined by transit alone. Meals alter multiple physiological processes simultaneously.
• Extrapolation requires caution. A transit model developed for one population or condition may not automatically apply to another.

Regulatory PBPK guidance emphasizes that the quality, relevance, and reliability of the model and its inputs matter when PBPK analyses are used to support regulatory applications. :contentReference[oaicite:8]{index=8}

23. A Practical Workflow for GI Transit in PBPK

1. Define the scientific question. Are you predicting food effects, formulation performance, regional absorption, a drug interaction, or population differences?
2. Define the GI physiology. Identify the relevant gastric and intestinal regions.
3. Select transit parameters. Use evidence appropriate to the population and physiological state.
4. Represent gastric emptying. Specify how drug leaves the stomach and enters the small intestine.
5. Represent intestinal transit. Use an appropriate regional or distributed transit model.
6. Connect transit to dissolution. Determine how much drug is available for absorption as it moves through each region.
7. Connect transit to absorption. Account for regional permeability and other absorption mechanisms.
8. Include intestinal metabolism when relevant. Drug entering enterocytes may undergo first-pass metabolism before reaching systemic circulation.
9. Simulate physiological conditions. For example, compare fed and fasted physiology when a food-effect question is being studied.
10. Perform sensitivity analysis. Determine whether transit assumptions materially affect predicted PK.
11. Validate the model. Compare predictions with observed concentration-time or exposure data that are relevant to the intended application.
12. Document assumptions. Clearly identify physiological inputs, drug-specific parameters, calibrated quantities, and uncertainty.

Where to Go Next

A natural next step is to study mechanistic absorption models in PBPK, where gastrointestinal transit is connected explicitly to dissolution, precipitation, permeability, intestinal surface area, transporters, and regional metabolism.

From there, the framework can be extended to drug dissolution and solubility, intestinal permeability, food-effect modeling, and eventually full physiologically based oral absorption models.

References

1. Kumral D, Zfass AM. Gut Movements: A Review of the Physiology of Gastrointestinal Transit. Digestive Diseases and Sciences. 2018;63:2500–2506. PMID: 30145693.
2. Liang X, et al. Physiologically Based Pharmacokinetic (PBPK) Modeling of Oral Drug Absorption for Integrating Nonclinical Data into Human Pharmacokinetic Predictions. AAPS Journal. 2026.
3. FDA. Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry. U.S. Food and Drug Administration. 2018.
4. FDA. The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls. U.S. Food and Drug Administration. Draft Guidance. 2020.
5. Christensen H, et al. Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool. 2020.
6. Wu D, et al. Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept. Pharmaceutical Research. 2023;40:419–429.
7. Gastrointestinal Transit Times in Health as Determined Using Ingestible Capsule Systems: A Systematic Review. 2023.
8. Simulations Plus. GastroPlus ACAT Model. Advanced Compartmental Absorption and Transit modeling framework for mechanistic oral absorption.